La mission du réseau ThéCell est de promouvoir la recherche translationnelle en thérapie cellulaire, tissulaire et génique au Québec, avec une vision de rayonnement international. Notre objectif principal est de favoriser la translation vers la clinique des thérapies cellulaires, tissulaires et géniques au profit de la santé de la population.
Attiogbe E, Larochelle S, Chaib Y, Mainzer C, Mauroux A, Bordes S, et al. An in vitro autologous, vascularized, and immunocompetent Tissue Engineered Skin model obtained by the self-assembled approach. Acta Biomater. 2023. Epub 20230705. doi: 10.1016/j.actbio.2023.06.045. PubMed PMID: 37419164.
Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, et al. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD. Transplant Cell Ther. 2023;29(1):44 e1- e9. Epub 20221102. doi: 10.1016/j.jtct.2022.10.022. PubMed PMID: 36334654
Dagher J, Arcand C, Auger FA, Germain L, Moulin VJ. The Self-Assembled Skin Substitute History: Successes, Challenges, and Current Treatment Indications. J Burn Care Res. 2023;44(Supplement_1):S57-S64. doi: 10.1093/jbcr/irac074. PubMed PMID: 36567476; PubMed Central PMCID: PMCPMC9790893.
Deprez A, Orfi Z, Rieger L, Dumont NA. Impaired muscle stem cell function and abnormal myogenesis in acquired myopathies. Biosci Rep. 2023;43(1). doi: 10.1042/BSR20220284. PubMed PMID: 36538023.
